All In Biotech

Drug Trial Radar · NCT07940582

A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or Obesity

A First-in-human Dose Study Investigating Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC0721-5186 in Female Participants Living With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Nov 13, 2026

Primary completion

May 29, 2028

Study completion May 29, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to look at the safety and how the body takes up, breaks down and removes NNC0721-5186 in people living with overweight or obesity when compared to placebo. In the first 3 dosing groups, NNC0721-5186 will also be compared with semaglutide, a medicine already approved for weight management. Participants will either get NNC0721-5186, semaglutide, or placebo. Which treatment participants get is decided by chance.

Conditions

  • Overweight
  • Obesity

Interventions

  • NNC0721-5186Drug

    NNC0721-5186 is administered as a single subcutaneous injection.

  • SemaglutideDrug

    Semaglutide is administered as a single subcutaneous injection using a pen-injector.

  • Placebo (NNC0721-5186)Drug

    Placebo is administered as a single subcutaneous injection matching NNC0721-5186.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment-emergent adverse events (TEAEs)Time frame: From time of dosing (Day 1) to Day 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • [Legal] Altasciences Clinical Los Angeles, Inc. & Altasciences Professional Los Angeles, P.C.

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.